ArticleFrontiers in pharmacology2026
Integrated metabolomics and machine learning identify predictive biomarkers via SHAP analysis for sintilimab-induced rash in lung cancer patients.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sintilimab-induced rash is a significant clinical challenge in lung cancer treatment, often necessitating therapy interruption or discontinuation and thereby compromising patient outcomes. The underlying mechanisms of this adverse event remain poorly understood. This study aimed to investigate potential predictive biomarkers and mechanisms of sintilimab-induced rash through metabolomic profiling. Methods: A total of 55 patients with lung cancer who received sintilimab were enrolled, including 32 who developed rash and 23 matched controls without rash. Blood samples were collected before sintilimab infusion and at rash onset. Comprehensive clinical data were recorded. Untargeted metabolomic analysis of plasma was performed using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Differential metabolites were identified and analyzed using pathway enrichment, univariate analysis (AUC ≥0.800), and SHAP analysis. Results: No significant differences were observed between groups in demographic characteristics or most clinical parameters. However, the rash group exhibited significantly elevated total bile acids glucose (GLU), and basophil percentage (BAS%), along with reduced AST/ALT ratio, alkaline phosphatase lactate dehydrogenase phosphorus (P), neutrophil count (NEU), and high-sensitivity C-reactive protein (hsCRP) (P < 0.05). Metabolomic analysis identified 92 differentially expressed metabolites. Pathway enrichment revealed alterations in oxytocin signaling, GnRH signaling, platelet activation, FcγR-mediated phagocytosis, retrograde endocannabinoid signaling, pantothenate and CoA biosynthesis, FcεRI signaling, and aldosterone synthesis and secretion. Univariate analysis identified 25 metabolites with high predictive value (AUC ≥0.800), and SHAP analysis highlighted 20 metabolites. Cross-comparison identified five overlapping metabolites: N,N,N-trimethyl-L-histidine, laurolactam, 2-naphthalenesulfonic acid, limonenecarboxylic acid, and N-lauroylsarcosine. Conclusion: Distinct clinical and metabolomic alterations are associated with sintilimab-induced rash in lung cancer patients. The identified differential metabolites may serve as predictive biomarkers and potential therapeutic targets, providing new insights for clinical management and mechanistic research into immune-related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.